lungs with bio marker

N115 Nasal Spray Found to Improve Lung Function in PF Patients

N115 Nasal Spray Found to Improve Lung Function in PF Patients

by Patricia Inacio PhD | October 11, 2021

SHARE THIS ARTICLE:

SHARE ARTICLE VIA EMAILCOPY ARTICLE LINK

lungs with bio marker

Biomarker in IPF lungs

Treatment with N115, EmphyCorp’s non-steroidal nasal spray, led to statistically and clinically significant improvements across all lung function parameters in patients with pulmonary fibrosis (PF) participating in a Phase 3 trial, data show.

Now, data from two other Phase 3 clinical trials suggest that N115 also may be beneficial for people infected with SARS-CoV-2, the virus that causes COVID-19, including “long haulers” — patients who continue experiencing symptoms of the disease long after testing negative. Long-term COVID-19 symptoms may include low oxygen levels, fatigue, coughing or sneezing, trouble breathing, body aches, headaches, and PF.

“Based upon the results of our three Phase III clinical trials, EmphyCorp [prescription] N115 non-steroidal nasal spray could be used as a safe, effective treatment to help alleviate the symptoms associated with COVID-19 infections, pulmonary fibrosis, and Long COVID-19 (Long Hauler) symptoms,” Alain Martin, PhD, CEO of EmphyCorp, said in a press release.